Trials / Completed
CompletedNCT04863794
A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants
A Non-Randomized, Open-Label, Adaptive, Single Center, Positron Emission Tomography (Pet) Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Male
- Age
- 25 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The aim of Study BP41660 is to quantify the amount and concentration of \[89Zr\]DFO-RO7248824 in the brain with positron emission tomography (PET) following a single sub-pharmacological dose of RO7248824 and \[89Zr\]DFO-RO7248824 administered via IT injection to healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7248824 | A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants. |
Timeline
- Start date
- 2021-04-29
- Primary completion
- 2022-08-01
- Completion
- 2022-08-01
- First posted
- 2021-04-28
- Last updated
- 2022-09-08
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04863794. Inclusion in this directory is not an endorsement.